197 related articles for article (PubMed ID: 12455205)
1. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
[TBL] [Abstract][Full Text] [Related]
2. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
Robinson DM; Keating GM
Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
[TBL] [Abstract][Full Text] [Related]
3. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
[TBL] [Abstract][Full Text] [Related]
4. Dexmethylphenidate.
Keating GM; Figgitt DP
Drugs; 2002; 62(13):1899-904; discussion 1905-8. PubMed ID: 12215063
[TBL] [Abstract][Full Text] [Related]
5. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
Moen MD; Keam SJ
CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
[TBL] [Abstract][Full Text] [Related]
6. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
McGough JJ; Pataki CS; Suddath R
Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
[TBL] [Abstract][Full Text] [Related]
7. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Sugrue D; Bogner R; Ehret MJ
Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
[TBL] [Abstract][Full Text] [Related]
8. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
[TBL] [Abstract][Full Text] [Related]
9. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
Childress AC; Spencer T; Lopez F; Gerstner O; Thulasiraman A; Muniz R; Post A
J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):351-61. PubMed ID: 19702487
[TBL] [Abstract][Full Text] [Related]
14. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
Quinn D
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
[TBL] [Abstract][Full Text] [Related]
15. Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder.
Kowalik S; Minami H; Silva R
Expert Opin Pharmacother; 2006 Dec; 7(18):2547-57. PubMed ID: 17150008
[TBL] [Abstract][Full Text] [Related]
16. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
Swanson JM; Lerner M; Wigal T; Steinhoff K; Greenhill L; Posner K; Freid J; Wigal S
J Atten Disord; 2002; 6 Suppl 1():S73-88. PubMed ID: 12685522
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
Silva RR; Muniz R; Pestreich L; Childress A; Brams M; Lopez FA; Wang J
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):239-51. PubMed ID: 16768632
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
[TBL] [Abstract][Full Text] [Related]
19. Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Pheils J; Ehret MJ
Am J Health Syst Pharm; 2021 May; 78(10):840-849. PubMed ID: 33954419
[TBL] [Abstract][Full Text] [Related]
20. Dexmethylphenidate (Focalin) for ADHD.
Med Lett Drugs Ther; 2002 May; 44(1130):45-6. PubMed ID: 12011757
[No Abstract] [Full Text] [Related]
[Next] [New Search]
